Normal at any cost: tall girls, short boys, and the medical industry's quest to manipulate height

2009 ◽  
Vol 47 (03) ◽  
pp. 47-1450-47-1450
Keyword(s):  
2006 ◽  
Vol 160 (10) ◽  
pp. 1035 ◽  
Author(s):  
Joyce M. Lee ◽  
Joel D. Howell
Keyword(s):  

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S170-S173 ◽  
Author(s):  
OLAV TRYGSTAD

Abstract In 1980-1985 680 preadolescent tall girls were treated with pharmacological doses of oestrogen to reduce final height. Indications for the therapy were predicted final height >+2.5 SD (180.75 cm), idiopathic scoliosis, and psychosocial problems. Until 1976 141 girls were given diethyl stilboestrol 5 mg daily. By advice of Prader this was then replaced by ethinyl oestradiol and a progestin was given on days 5-10 each month. The mean duration of therapy was close to 2 years. The observed short-term unwanted effects were due to the pharmacological actions of the drugs, (11 girls had galactorrhoea at the end of therapy; no pituitary prolactionoma was observed) or events happening by chance.


PEDIATRICS ◽  
1978 ◽  
Vol 62 (6) ◽  
pp. 1091-1097
Author(s):  
Felix A. Conte ◽  
Melvin M. Grumbach

Members of the Lawson Wilkins Pediatric Endocrine Society (LWPES) and the European Society of Pediatric Endocrinology (ESPE) were mailed a questionnaire to survey their views and practices with respect to the use of estrogens in children and adolescents. The purpose of this survey was to ascertain the prevalence of estrogen therapy in children and adolescents, as well as the estrogen preparation used, dose, benefits, and observed complications. Seventy-four of 213 LWPES members or groups and 29 of 106 ESPE members or groups returned the survey. The lack of rapid retrieval systems in many clinics and the necessity for return of the survey data within a ten-week period precluded many respondents from the exhaustive, careful chart reviews necessary to answer many of the questions posed. Accordingly, data generated in this survey must be interpreted in this light. Estrogens are used primarily in children and adolescents for (1) the treatment of tall stature, (2) replacement therapy in hypogonadal adolescents, and (3) as a component of contraceptive pills given to sexually active teenagers. ESTROGEN TREATMENT OF TALL GIRLS The treatment of "excessively" tall adolescent girls with pharmacologic doses of estrogen, in an attempt to decrease mature height, has been a subject of controversy since its inception by Goldzieher1 in 1956; 50% of the LWPES and 17% of the ESPE respondents indicated that they never treat "tall" girls with pharmacologic doses of estrogen, basing their decision primarily on the fact that the long-term side effects of such doses of estrogens are unknown. In addition, the risk-benefit ratio and the fact that tall stature is not a disease were other important reasons for not treating these girls.


1979 ◽  
Vol 91 (1) ◽  
pp. 19-29 ◽  
Author(s):  
J. P. Hanker ◽  
G. Schellong ◽  
H. P. G. Schneider

ABSTRACT Sixteen excessively tall girls were treated with 0.3 mg of ethinyloestradiol daily and 10 mg of norethisterone for 5 days every 3 weeks for 7–26 months. The reduction of adult height varied from 0–12.3 cm, depending on the bone age (115/12–148/12) before treatment. The more advanced the bone age was the less final adult height was reduced. The functional state of the hypothalamo-pituitary axis was assessed by standardized LH-RH testing immediately after termination of therapy as well as 1, 4, 8 and 12 weeks thereafter. Basal levels of oestradiol and prolactin were recorded before each test. Absent LH-responses to LH-RH were observed in all girls when therapy was stopped. Four to eight weeks later the LH responses had normalized in 13 girls and 12 weeks after therapy normal LH responses were found in 14 girls. Mean basal oestradiol levels were low (20 ± 9 pg/ml) (X̄ ± sd) at the end of therapy but increased significantly (P < 0.0025) to levels similar to different stages of the menstrual cycle after 4 weeks. In contrast mean basal prolactin levels were elevated (21±9 ng/ml) (X̄ ± sd) when therapy was stopped. Within one week a significant (P < 0.01) decrease to values averaging 13 ± 4 ng/ml (sd) was seen. A further but only moderate decline occurred until the 12th week after therapy. The decrease of prolactin paralleled to same extend the increase of endogenous oestradiol. All girls experienced spontaneous menstrual bleedings within 3 to 22 weeks after termination of therapy. In all cases but one menses have been regular since. The data presented suggest that no major functional disturbance of the hypothalamo-pituitary axis has to be expected after long-term steroid treatment in excessively tall girls.


1969 ◽  
Vol 24 (2) ◽  
pp. 177???178
Author(s):  
S. DOUGLAS FRASIER ◽  
FRED G. SMITH
Keyword(s):  

1982 ◽  
Vol 100 (3) ◽  
pp. 327-332 ◽  
Author(s):  
John S. G. van den Bosch ◽  
Anthony G. H. Smals ◽  
Gerlach F. F. M. Pieters ◽  
Ignace M. Valk ◽  
Peter W. C. Kloppenborg

Abstract. A major problem in the androgen treatment of escessive height in boys is acceleration of growth velocity especially in the early stages of therapy. Oestrogen treatment in tall girls, in contrast, instantly decelerates growth velocity, probably by its plasma somatomedin lowering effect. As oestrogen administration in male subjects causes a similar somatomedin depression and immediate growth inhibition is also wanted in the treatment of excessive height in boys, the effect of short-term low dose oestrogen therapy (ethinyloestradiol, Ee, Lynoral®, 0.050 mg daily) on growth was studied in 10 constitutionally tall boys. During oestrogen therapy three week ulnar growth rate (TUG-rate) dropped instantly from 0.84 ± 0.42 to 0.33 ± 0.27 mm (P < 0.02) within 6 weeks. Three week body growth rate also changed significantly from 0.48 ± 0.23 to 0.12 ± 0.37 cm during oestrogen loading (P < 0.05). The magnitude of the latter changes, however, allows only evaluation of the whole group, whereas changes in TUG-rates far exceeded the limits of confidence in most individual boys. Growth deceleration during Ee was accompanied by a significant decrease in serum alkaline phosphatase activities (from 299 ± 72 U/l before to 240 ± 79 U/l during Ee, P < 0.01), plasma calcium (from 2.45 ± 0.06 to 2.35 ± 0.05 mmol/l during Ee, P < 0.05) and plasma testosterone levels (from 392 ± 128 ng/100 ml before to 27 ± 7 ng/100 ml during Ee, P < 0.005). Within 2 months after stopping Ee administration plasma testosterone levels were normal again (432 ± 282 ng/100 ml). Testicular size was not affected. Mild reversible gynaecomastia, however, was present in all boys. The results demonstrate an instant growth decelerating effect of low dose oestrogen administration in tall boys reminiscent to the findings in tall girls under the same low dose regimen. Furthermore these data provide a theoretical base for combining androgens and oestrogens in the early stages of treatment of excessive height in boys in order to antagonize the initial growth accelerating effect of androgens alone.


Sign in / Sign up

Export Citation Format

Share Document